updated 11/12/2010 4:47:13 PM ET 2010-11-12T21:47:13

FLORENCE, Ky., Nov. 12, 2010 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD), announced today that Sven Rohmann, M.D., Ph.D., a member of the Company's Scientific Advisory Board, will deliver the Immudyne company presentation at BIO-Europe on November 16, 2010. BIO-Europe is Europe's premier biotechnology conference. 

Dr. Rohmann will be presenting clinical outcome data (survival) regarding Immudyne's ultra pure beta glucan product administered orally for innate immunity support in 99 critically ill cancer patients. This clinical trial provides first clinical proof of efficacy as well as insights into the mechanism of action of Immudyne`s lead product.

In addition, clinical evidence will be provided that Immudyne`s liquid formulation of beta glucan stimulates topically the skin repair mechanisms via innate immunity effector cells, thereby reducing skin firmness and the signs of aging, as well as providing some skin protection against UV light.

About Immudyne

Immudyne is a biotechnology company that possesses an array of patent protected processes for the extraction of beta blucan from yeast in the most pure form available. Immudyne's products are currently being used in the nutraceutical field to aid in immune system support, in skin creams to reduce the signs of aging, and in the animal feeds industry as a substitute for antibiotics. Immudyne's processing facilities are located in Florence, Kentucky. Its products are sold globally.

ImmuDyne shares trade under the ticker symbol IMMD (PK) and the Company can be found on the web at www.immudyne.com (currently being transformed).

Cautionary language regarding Forward-Looking Statements

Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com